about
THERAPY OF ENDOCRINE DISEASE: Surgery in microprolactinomas: effectiveness and risks based on contemporary literatureRecent advances in the management of acromegalyDiabetes Insipidus after Traumatic Brain InjuryNelson's syndromeEpidemiology of acromegaly: review of population studies.Rathke's cleft cyst.Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 PatientsOpioid induced hypogonadism.Recurrent and/or metastatic thyroid cancer: therapeutic options.Radiation-induced hypopituitarism.Whole-exome sequencing studies of nonfunctioning pituitary adenomas.Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up.Treatment of pituitary tumors: history.Craniopharyngiomas.Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.Hypopituitarism oddities: craniopharyngiomas.Radiotherapy of other sellar lesions.Craniopharyngiomas. Historical aspects of their management.Non-adenomatous pituitary tumours.Adrenal insufficiency in acute oral opiate therapy.The postoperative monitoring of nonfunctioning pituitary adenomas.Mini-review: pheochromocytomas causing the ectopic ACTH syndrome.Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.Prevalence and incidence of pituitary adenomas.Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.The management of head-and-neck paragangliomas.Management of craniopharyngiomas.Clinical review: Functioning gonadotroph adenomas.Diagnosis and management of prolactinomas and non-functioning pituitary adenomas.Management of endocrine disease: pituitary tumour apoplexy.Clinical and biochemical manifestations of Cushing's.Efficacy and complications of pituitary irradiation.Pituitary disorders in pregnancy.Treating prolactinomas with dopamine agonists: always worth the gamble?Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway.A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up.Recent advances in molecular pathology of craniopharyngioma.
P50
Q26747177-2C10EA12-17FA-4F8F-8002-FF46D98DAC29Q26766199-C32624C9-87DE-4E44-875A-AADD16234844Q26799420-36C7E187-D427-44B0-9CFA-B88FCDCDE5EAQ28289136-31D4096B-BC97-4DF4-839D-6CC569D55380Q30244550-0185BF4C-A858-4781-95C7-FD6D2E6C1649Q30854698-9AAF421E-F1E1-43E5-B076-B30AF01A549EQ33569920-64B18CB0-1ACC-4299-9671-D2E41FC66406Q34023723-E20F1358-67F4-4F26-8271-56F1B73F374DQ34706919-3C2FFB87-245C-40AF-9DC2-458E90465930Q34985025-C80AD780-FB2A-4C10-93AC-49341540D496Q35661976-05BC4FD9-1DC7-4349-9319-97DE0DB30883Q36088358-13FCFCEB-6377-4217-851A-065D45BE6875Q36324153-8E6ABE9E-1883-4FF4-82C7-DF0477C73047Q36423600-AF7D9E06-906A-4A32-A64C-F6629AE99839Q36489627-4D771B25-E89A-4009-8F19-ED2A93B5826DQ36730944-7FF3E3AF-D19A-4AE6-A8A9-739EAC1179C6Q37050098-D644E7B1-78A3-42DF-9954-3D8FA998C6A5Q37128832-32C27729-02FC-40B6-AA60-A3A7E94D45F2Q37241398-BE5393FB-DE2D-48A3-BB0B-81F746B9020EQ37640644-B0DE5FB6-2EBE-49ED-BB53-46D725104DC4Q37662269-BB0D0F26-49BC-4034-87F1-7CF40C4258D3Q37862061-F37FC974-8EA3-4260-8039-2B049C42A11DQ37991253-6716F134-ACEB-48DC-935E-661828543455Q38001924-E2FFBC96-4910-4758-A81D-FAE5C1F5908EQ38004115-12998D50-8BFF-4A86-A863-7F75F118EBA1Q38009284-C4887F17-5210-4CC2-B5A6-531446955C00Q38127079-3B14FA02-8CD0-4065-B59E-2A6A94021F2BQ38183324-0B8024FB-7A8D-4FD0-BC1D-6252290A5A21Q38244197-E5BD245E-283D-4934-B3FB-517E52F1306EQ38248137-18BC7DD5-3313-42F9-9533-F1BA1D5672A9Q38276298-F613DD84-E9E9-415F-82AA-647506735537Q38311631-5560B939-1404-40D3-ABE1-1CCD653FB7A9Q38366915-6A87AB65-0A5B-4DCB-86A0-612BF98F7D8EQ38426012-5B1EC685-F560-44AD-B822-8F8FE2742B8DQ38580100-CC8C617C-E5BF-449C-96AC-9A2E51B0C373Q39338191-28C105DD-3439-40D8-84D8-DB9C3F110BCBQ39444064-EDA2EB33-364C-4C9C-9F5E-4552A838AC56Q39707930-B6B035CC-A1D7-4C4B-8220-4990DE5AEF4DQ40346353-C5D92728-BDA6-43DD-B932-D647526C3FE8Q41150936-C94640B0-CA29-4A8E-A220-157064046708
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Niki Karavitaki
@ast
Niki Karavitaki
@en
Niki Karavitaki
@es
Niki Karavitaki
@nl
type
label
Niki Karavitaki
@ast
Niki Karavitaki
@en
Niki Karavitaki
@es
Niki Karavitaki
@nl
altLabel
NIKI KARAVITAKI
@en
prefLabel
Niki Karavitaki
@ast
Niki Karavitaki
@en
Niki Karavitaki
@es
Niki Karavitaki
@nl
P106
P21
P31
P496
0000-0002-4696-0643